First-line tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A post-hoc analysis of different investigator-choice CT and tumor PD-L1 expression level subgroups in RATIONALE-306

Authors
Category Primary study
ConferenceEuropean Society For Medical Oncology Congress, ESMO 2025
Year 2025
This article has no abstract
Epistemonikos ID: b0a73942902dbccbab27f48ca82f943133d367f7
First added on: May 16, 2026